title: A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20 mm), with a 12-month follow-up.
abstract: OBJECTIVE
  To compare the efficacy and cosmetic outcome (CO) of photodynamic therapy with topical methyl aminolevulinate (MAL-PDT) with simple excision surgery for superficial basal cell carcinoma (sBCC) over a 1-year period.
  
  
  METHODS
  In this multicentre, randomised, controlled, open study, patients were treated at baseline either with MAL-PDT (two sessions, 7 days apart, repeated 3 months later if incomplete clinical response) or surgery (at baseline). Primary endpoints were clinical lesion response (CR) 3 months after last treatment and CO assessed by the investigator 12 months after last treatment. Secondary endpoints were CR at 12 months (i.e. recurrence) and CO assessed by the investigator at 3 and 6 months and by the patient at 3, 6 and 12 months.
  
  
  RESULTS
  Overall, 196 patients were enrolled with 1.4 sBCC lesions on average per patient. Mean lesion count reduction at 3 months was 92.2% with MAL-PDT vs. 99.2% with surgery [per protocol (PP) population] confirming the non-inferiority hypothesis (95% confidence interval, -12.1, -1.9). A total of 92.2% lesions showed CR at 3 months with MAL-PDT vs. 99.2% with surgery (PP population). At 12 months, 9.3% lesions recurred with MAL-PDT and none with surgery. CO was statistically superior for MAL-PDT at all time points. At 12 months, 94.1% lesions treated with MAL-PDT had an excellent or good CO according to the investigator compared with 59.8% with surgery. This difference was confirmed with the patients' assessment. The proportion of excellent CO markedly improved with time with MAL-PDT unlike surgery.
  
  
  CONCLUSIONS
  MAL-PDT offers a similarly high efficacy and a much better CO than simple excision surgery in the treatment of sBCC.
authors.affiliation: Klinikum der Universität, Regensburg, Germany. rolf-markus.szeimies@klinik.uni-regensburg.de
authors.forename: R M
authors.initials: RM
authors.lastname: Szeimies
authors.forename: S
authors.initials: S
authors.lastname: Ibbotson
authors.forename: D F
authors.initials: DF
authors.lastname: Murrell
authors.forename: D
authors.initials: D
authors.lastname: Rubel
authors.forename: Y
authors.initials: Y
authors.lastname: Frambach
authors.forename: D
authors.initials: D
authors.lastname: de Berker
authors.forename: R
authors.initials: R
authors.lastname: Dummer
authors.forename: N
authors.initials: N
authors.lastname: Kerrouche
authors.forename: H
authors.initials: H
authors.lastname: Villemagne
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000622:Aminolevulinic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002280:Basal Cell Carcinoma / Q000188:drug therapy* / Q000601:surgery*; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000601:surgery*; D016896:Treatment Outcome
chemical_list: D017319:Photosensitizing Agents; C475457:methyl 5-aminolevulinate; D000622:Aminolevulinic Acid